The following additional information regarding the remuneration for Dr Hal Barron, Chief Scientific Officer and President of R & D is provided for shareholders’ reference:

* GSK takes seriously its responsibility to set executive remuneration appropriately.
* Dr Barron’s remuneration was decided by the Remuneration Committee following a thorough process, including consideration of shareholder views.
* Dr Barron’s many years of experience as a world renowned Scientific Officer, long track record and experience in leadership in the global pharmaceutical industry, and the newly established role of Chief Scientific Officer and President of R&D, justify the pay differential in the context of the agreed market benchmark.
* GSK has stated that Dr Barron’s package will not be used as a rationale for changes to the remuneration of the CEO.